Meta-analysis of 35 RCTs (>20K pts) with inflammatory skin disorders shows that w/ short-term (<5 mos) use JAK inhibitors do not significantly increase risk of all-cause mortality (OR, 0.83; 0.44-1.57), MACE, or VTE (OR, 0.52; 0.26-1.04). https://t.co/zBlcZ02QqQ https://t.co/cXjswVS9lF